Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Lisa Bodei's publication output changed over time?
ScholarIQpublication output · 2005–2025
Output grew0% over the shown period — from 1 works in 2005 to 1 in 2025.
1
1
1
1
1
1
1
1
1
1
2005200820112013201420172019202020222025
What are the most-cited papers on Lisa Bodei?
ScholarIQmost cited works
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros, Lisa Bodei, Michael R. McDevitt, Jessie R. Nedrow
S186543748. 2020938 CitationsOPEN ACCESS
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand, Marianne E. Pavel, Richard P. Baum, Dieter Hörsch, M. Sue O’Dorisio, T. M. O’Dorisiol, James R. Howe, Marta Cremonesi, Dik J. Kwekkeboom
S191349260. 2013816 CitationsOPEN ACCESS
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei, Mark Kidd, Giovanni Paganelli, Chiara Maria Grana, Ignat Drozdov, Marta Cremonesi, Christopher Lepensky, Dik J. Kwekkeboom, Richard P. Baum, Eric P. Krenning, Irvin M. Modlin
S191349260. 2014469 Citations
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, Monica Pacifici, Chiara Maria Grana, Mirco Bartolomei, Silvia M. Baio, Maddalena Sansovini, Giovanni Paganelli
S191349260. 2008425 Citations
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei, Marta Cremonesi, Chiara Maria Grana, Nicola Fazio, Simona Iodice, Silvia M. Baio, Mirco Bartolomei, Dario Lombardo, Mahila Ferrari, Maddalena Sansovini, Marco Chinol, Giovanni Paganelli
S191349260. 2011423 Citations
Related on ScholarIQ
Memorial Sloan Kettering Cancer Center
Institution
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Paper
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
Paper
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Paper
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
Paper
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Paper